You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The prototype system uses viral genome data to act as a framework for real-time molecular epidemiology and evolutionary analysis of emerging epidemics.
The competition was established in 2015 to fund studies addressing the biggest challenges in cancer research.
GeneDx said it will contribute patient data and analytical tools to the UK's Deciphering Developmental Disorders study.
The new sequences also uncovered two new gene families likely involved in Plasmodium malariae's ability to invade host cells.
A British team discovered 14 novel genes associated with developmental disorders in addition to several new disorders linked to known genes.
Investigators uncovered 33 hotspots of large tandem duplications among breast cancer cases that affected cancer susceptibility genes and super-enhancers.
Based on genetic patterns in thousands of individuals with primary sclerosing cholangitis, researchers identified four new risk loci and explored ties to IBD.
The researchers will use single-cell genomics and other approaches to generate information that could ultimately be used to diagnose, monitor, and treat disease.
Illumina and the H3Africa Consortium hope the array will allow future GWAS to address African genomic diversity in a way that previous chips have not.
The partners will exchange all information they have on genetic mutations leading to cancer with an eye toward accelerating research and drug discovery efforts.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.